88 related articles for article (PubMed ID: 16316623)
1. Lovastatin-induced RhoA modulation and its effect on senescence in prostate cancer cells.
Lee J; Lee I; Park C; Kang WK
Biochem Biophys Res Commun; 2006 Jan; 339(3):748-54. PubMed ID: 16316623
[TBL] [Abstract][Full Text] [Related]
2. Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line.
Ghosh PM; Ghosh-Choudhury N; Moyer ML; Mott GE; Thomas CA; Foster BA; Greenberg NM; Kreisberg JI
Oncogene; 1999 Jul; 18(28):4120-30. PubMed ID: 10435593
[TBL] [Abstract][Full Text] [Related]
3. Lovastatin suppresses invasiveness of anaplastic thyroid cancer cells by inhibiting Rho geranylgeranylation and RhoA/ROCK signaling.
Zhong WB; Liang YC; Wang CY; Chang TC; Lee WS
Endocr Relat Cancer; 2005 Sep; 12(3):615-29. PubMed ID: 16172195
[TBL] [Abstract][Full Text] [Related]
4. Statin induces apoptosis and cell growth arrest in prostate cancer cells.
Hoque A; Chen H; Xu XC
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):88-94. PubMed ID: 18199714
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory role of RhoA on senescence-like growth arrest by a mechanism involving modulation of phosphatase activity.
Park C; Lee I; Jang JH; Kang WK
FEBS Lett; 2007 Aug; 581(20):3800-4. PubMed ID: 17658517
[TBL] [Abstract][Full Text] [Related]
6. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.
Shabbeer S; Kortenhorst MS; Kachhap S; Galloway N; Rodriguez R; Carducci MA
Prostate; 2007 Jul; 67(10):1099-110. PubMed ID: 17477369
[TBL] [Abstract][Full Text] [Related]
7. HMG-CoA reductase inhibitor simvastatin overcomes bortezomib-induced apoptosis resistance by disrupting a geranylgeranyl pyrophosphate-dependent survival pathway.
Fuchs D; Berges C; Opelz G; Daniel V; Naujokat C
Biochem Biophys Res Commun; 2008 Sep; 374(2):309-14. PubMed ID: 18625202
[TBL] [Abstract][Full Text] [Related]
8. Lovastatin-induced PC-12 cell differentiation is associated with RhoA/RhoA kinase pathway inactivation.
Fernández-Hernando C; Suárez Y; Lasunción MA
Mol Cell Neurosci; 2005 Aug; 29(4):591-602. PubMed ID: 15951198
[TBL] [Abstract][Full Text] [Related]
9. Simvastatin suppresses self-renewal of mouse embryonic stem cells by inhibiting RhoA geranylgeranylation.
Lee MH; Cho YS; Han YM
Stem Cells; 2007 Jul; 25(7):1654-63. PubMed ID: 17464088
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of cholesterol and phytosterols on cell proliferation, apoptosis and expression of a prostate specific gene in prostate cancer cell lines.
Ifere GO; Barr E; Equan A; Gordon K; Singh UP; Chaudhary J; Igietseme JU; Ananaba GA
Cancer Detect Prev; 2009; 32(4):319-28. PubMed ID: 19186008
[TBL] [Abstract][Full Text] [Related]
11. Tocotrienols potentiate lovastatin-mediated growth suppression in vitro and in vivo.
McAnally JA; Gupta J; Sodhani S; Bravo L; Mo H
Exp Biol Med (Maywood); 2007 Apr; 232(4):523-31. PubMed ID: 17392488
[TBL] [Abstract][Full Text] [Related]
12. The Survivin-mediated radioresistant phenotype of glioblastomas is regulated by RhoA and inhibited by the green tea polyphenol (-)-epigallocatechin-3-gallate.
McLaughlin N; Annabi B; Bouzeghrane M; Temme A; Bahary JP; Moumdjian R; Béliveau R
Brain Res; 2006 Feb; 1071(1):1-9. PubMed ID: 16412397
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of RhoA signaling on anticancer agent-induced cell death.
Kang WK; Lee I; Ko U; Park C
Oncol Rep; 2005 Feb; 13(2):299-304. PubMed ID: 15643515
[TBL] [Abstract][Full Text] [Related]
14. A non-characteristic response of L1210 cells to lovastatin.
Engelke KJ; Hacker MP
Biochem Biophys Res Commun; 1994 Aug; 203(1):400-7. PubMed ID: 8074684
[TBL] [Abstract][Full Text] [Related]
15. [Curcumin inhibits the expression of vascular endothelial growth factor and androgen-independent prostate cancer cell line PC-3 in vitro].
Deng G; Yu JH; Ye ZQ; Hu ZQ
Zhonghua Nan Ke Xue; 2008 Feb; 14(2):116-21. PubMed ID: 18390174
[TBL] [Abstract][Full Text] [Related]
16. FTY720, a fungus metabolite, inhibits invasion ability of androgen-independent prostate cancer cells through inactivation of RhoA-GTPase.
Zhou C; Ling MT; Kin-Wah Lee T; Man K; Wang X; Wong YC
Cancer Lett; 2006 Feb; 233(1):36-47. PubMed ID: 16473668
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells.
Merrell MA; Wakchoure S; Lehenkari PP; Harris KW; Selander KS
Eur J Pharmacol; 2007 Sep; 570(1-3):27-37. PubMed ID: 17640631
[TBL] [Abstract][Full Text] [Related]
18. PAR1-mediated RhoA activation facilitates CCL2-induced chemotaxis in PC-3 cells.
Loberg RD; Tantivejkul K; Craig M; Neeley CK; Pienta KJ
J Cell Biochem; 2007 Aug; 101(5):1292-300. PubMed ID: 17492768
[TBL] [Abstract][Full Text] [Related]
19. Neuropeptide-stimulated cell migration in prostate cancer cells is mediated by RhoA kinase signaling and inhibited by neutral endopeptidase.
Zheng R; Iwase A; Shen R; Goodman OB; Sugimoto N; Takuwa Y; Lerner DJ; Nanus DM
Oncogene; 2006 Sep; 25(44):5942-52. PubMed ID: 16652149
[TBL] [Abstract][Full Text] [Related]
20. [Inhibitory effects of lovastatin on the proliferation and cell cycle phase of cultured human glomerular mesangial cells in vitro].
Li H; Li XW; Duan L; Li CH
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2002 Feb; 24(1):63-6. PubMed ID: 12905842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
